Bristol-Myers withdraws Opdivo/Yervoy lung cancer EU application — but others are incoming
Early in 2019, Bristol-Myers Squibb rescinded an FDA application to market its checkpoint inhibitor Opdivo in combination with its CTLA-4 therapy Yervoy for frontline use in patients with the most common form of lung cancer. One year later — the company is taking the same step with the European regulator.
Despite a head start, when Bristol-Myers’ and its pioneering checkpoint inhibitor Opdivo suffered a key lung cancer setback in 2016 — they found themselves relegated to the backseat as Merck’s Keytruda seized the wheel on the road to immunotherapy stardom. The drugmaker has since suffered a series of blows in its quest to take a big slice of the lucrative market, peppered with some successes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
